耐氟康唑念珠菌和耐伊曲康唑烟曲霉对泊沙康唑的敏感性测定

中国真菌学杂志　 2014, Vol. 9 　Issue (2): 75-78.

耐氟康唑念珠菌和耐伊曲康唑烟曲霉对泊沙康唑的敏感性测定

王雪洁, 万喆, 李若瑜, 刘伟

北京大学第一医院皮肤科北京大学真菌和真菌病研究中心皮肤病分子诊断北京市重点实验室, 北京 100034

收稿日期:2013-09-23 出版日期:2014-04-28 发布日期:2014-04-28
通讯作者: 刘伟，liuwei@bjmu.edu.cn E-mail:liuwei@bjmu.edu.cn
作者简介:王雪洁，女（汉族），硕士研究生在读.E-mail：wangxuejiehx@163.com
基金资助:
教育部“新世纪优秀人才支持计划”（NCET-10-0198）

Antifungal susceptibility testing of clinical isolates of fluconazole-resistant Candida spp. and itraconazole-resistant Aspergillus funmigates to posaconazole

WANG Xue-jie, WAN Zhe, LI Ruo-yu, LIU Wei

Department of Dermatology and Venereology, Peking University First Hospital, Research Center for Medical Mycology, Peking University, Beijing 100034, China

Received:2013-09-23 Online:2014-04-28 Published:2014-04-28

摘要/Abstract

摘要：

目的测定耐氟康唑念珠菌和耐伊曲康唑烟曲霉临床分离株对泊沙康唑的敏感性。方法参照美国临床实验室标准化研究所制定的M27-A3和M38-A2方案，测定从临床获得的11株耐氟康唑的念珠菌和3株耐伊曲康唑烟曲霉对泊沙康唑的MIC值。结果对于氟康唑耐药的念珠菌，泊沙康唑的MIC范围是0.125~1 μg/mL。对于伊曲康唑耐药烟曲霉，泊沙康唑的MIC范围是0.06~0.5 μg/mL。结论 11株耐氟康唑的念珠菌和3株耐伊曲康唑烟曲霉均对泊沙康唑有效。

关键词: 耐药性, 念珠菌, 烟曲霉, 泊沙康唑

Abstract:

Objective To determine the in vitro susceptibility of fluconazole (FLU)-resistant Candida spp. and itraconazole (ITC)-resistant Aspergillus spp. to posaconazole (POS).Methods The MICs of FLU, ITC, voriconazole (VRC) and POS were determined according to CLSI M27-A3 and M38-A2 methods in eleven isolates of Candida spp. and three isolates of Aspergillus spp.Results MICs of FLU, ITC, VRC and POS against FLU-resistant Candida spp. were 64 μg/mL, 0.5~16 μg/mL, 0.25~2 μg/mL and 0.125~1 μg/mL. And MICs of ITC, VRC and POS against ITC-resistant Aspergillus spp. were >16 μg/mL, 1~2 μg/mL and 0.25~0.5 μg/mL.Conclusion POS is effective to FLU-resistant Candida spp. and ITC-resistant Aspergillus spp. in vitro.

Key words: drug resistance, Candida, Aspergillus fumigatus, posaconazole

中图分类号:

R978.5

王雪洁, 万喆, 李若瑜, 刘伟. 耐氟康唑念珠菌和耐伊曲康唑烟曲霉对泊沙康唑的敏感性测定[J]. 中国真菌学杂志, 2014, 9(2): 75-78.

WANG Xue-jie, WAN Zhe, LI Ruo-yu, LIU Wei. Antifungal susceptibility testing of clinical isolates of fluconazole-resistant Candida spp. and itraconazole-resistant Aspergillus funmigates to posaconazole[J]. Chinese Journal of Mycology, 2014, 9(2): 75-78.

参考文献

[1] Silva S, Negri M, Henriques M, et al.Candida glabrata,Candida parapsilosis and Candida tropicalis:biology, epidemiology, pathogenicity and antifungal resistance[J]. FEMS Microbiol Rev, 2012, 36(2): 288-305.
[2] 陈翠珠, 徐英春, 王澎, 等. 1557株酵母菌的鉴定及其药敏试验分析[J]. 中国真菌学杂志,2006, 1(3): 134-138.
[3] Rodloff C, Koch D, Schaumann R. Epidemiology and antifungal resistance in invasive candidiasis[J]. Eur J Med Res, 2011, 16(4): 187-195.
[4] Wang H, Xiao M, Chen SC, et al.In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study[J]. J Clin Microbiol, 2012, 50(12): 3952-3959.
[5] Pfaller MA, Diekema DJ, Ghannoum MA, et al. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods[J]. J Clin Microbiol, 2009, 47(10): 3142-3146.
[6] Denning DW, Hope WW. Therapy for fungal diseases: opportunities and priorities[J]. Trends Microbiol, 2010, 18(5): 195-204.
[7] Warrilow AG, Melo N, Martel CM, et al. Expression, purification, and characterization of Aspergillus fumigates sterol 14-alpha demethylase (CYP51) isoenzymes A and B[J]. Antimicrob A gents Chemother, 2010, 54(10): 4225-4234.
[8] Nagappan V, Deresinski S. Reviews of anti-infective agents: Posaconazole: a broad-spectrum triazole antifungal agent[J]. Clin Infect Dis, 2007, 45(12): 1610-1617.
[9] Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts[S]. Approved standard-Third edition M27-A3. CLSI, Wayne, PA, 2008.
[10] Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi[S]. Approved standard-Second edition M38-A2. CLSI, Wayne, PA, 2008.
[11] Pfaller M, Boyken L, Hollis R, et al. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin[J]. Journal of clinical microbiology, 2011, 49(2): 624-629.
[12] Verweij PE, Howard SJ, Melchers WJ, et al. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints[J]. Drug Resist Update, 2009, 12(6): 141-147.
[13] Mishra NN, Prasad T, Sharma N, et al. Pathogenicity and drug resistance in Candida albicans and other yeast species. A review[J]. Acta Microbiol Immunol Hung, 2007, 54(3): 201-235.
[14] Mayr A, Lass-Fl?rl C. Epidemiology and antifungal resistance in invasive Aspergillosis according to primary disease: review of the literature[J]. Eur J Med Res, 2011, 16(4): 153-157.
[15] Kriengkauykiat J, Ito JI, Dadwal SS. Epidemiology and treatment approaches in management of invasive fungal infections[J]. Clin Epidemiol, 2011, 3(1):175-191.
[16] 芦现杰, 郑玉果, 周斌. 真菌对唑类药物耐药机制研究进展[J]. 世界临床药物, 2012, 33(6): 363-368.
[17] 索桂英, 付萍. 白念珠菌氟康哇耐药机制的研究进展[J]. 皮肤病与性病, 2013, 5(2): 90-94.
[18] 孙毅, 刘伟, 陈伟, 等. 对唑类药物交叉耐药的烟曲霉临床分离株耐药机制的初步探讨[J]. 中华皮肤科杂志, 2011, 44(4): 244-248.
[19] Schiller DS, Fung HB. Posaconazole: an extended-spectrum triazole antifungal agent[J]. Clin Ther,2007, 29(9): 1862-1886.
[20] Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease[J]. N Engl J Med, 2007, 356(4): 335-347.
[21] Xiao L, Madison V, Chau AS, et al. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14α-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding[J]. Antimicrob Agents Chemother,2004,48:568-574.